Lumos Diagnostics Holdings Ltd. (AU:LDX) has released an update.
Lumos Diagnostics reports a 6% revenue increase to $11.1 million for FY2024, driven by a significant 289% surge in product revenue and strategic agreements with women’s health firm Hologic. The company also celebrated FDA clearances for its FebriDx and ViraDx point-of-care tests, enhancing their market presence. A successful $5 million capital raise and positive net operating cashflow further underscore Lumos’s financial upswing.
For further insights into AU:LDX stock, check out TipRanks’ Stock Analysis page.
